Takeda’s flagship product panitumumab (PAN) + mFOLFOX6 versus bevacizumab (BEV) + mFOLFOX6 demonstrated better outcomes in primary endpoints for the Left-sided tumor population in metastatic colorectal cancer (mCRC).